Modernizing TBdiagnosis worldwide.
HerelleX began as a university spin-off built on two decades of bacteriophage and tuberculosis research.
Our mission
Developing innovative solutions for tuberculosis in the 21st century.
01.
Access to diagnosis
Make accurate TB diagnosis affordable and available where it's needed most.
02.
Accelerate drug discovery
Use our phage platform as a screening engine for next-generation antibacterials.
03.
Shorter, simpler treatment
Guide therapy with real-time resistance and treatment-monitoring data.
Why us
Twenty years of research,built for the real world.
HerelleX is built on two decades of work in phage biology and TB diagnostics. We're not chasing a trend — we're industrializing science that has already proven itself in the lab. Today we're a funded start-up, preparing FluoTB's regional and global launch.
MVP clinical validation completed.
years of phage & TB science.
from leading Argentine universities.
a platform, not a single product.
Leadership
The people behindthe company.
A founding team where deep science meets execution — bridging the lab, the clinic and the market.
Agustín Seijo
CEO
Leads strategy, regulatory path and commercial partnerships toward market entry.
Florencia Payaslian
CSO
Heads the science — translating phage engineering into a robust clinical product.
Mariana Piuri
Founder
Two decades in bacteriophage biology and TB diagnostics; the scientific origin of HerelleX.
Board & Advisors
Paul Elberse
Board Director
Guides business strategy and large-scale vision for HerelleX.
Carlos Batthyány
Board Director
Guides scientific and strategic direction as HerelleX grows.
Diego Melazzi
Advisor
Shapes financial strategy through experience in consulting and investment banking.
Vanesa Piattoni
Advisor
Drives innovation strategy through experience in technology transfer.
Get involved
Bring FluoTB to where it's needed.
The potential market is ~200,000 tests a year in Argentina and over 30 million a year across high-incidence countries — a global TB-diagnostics market projected to grow from USD 2.28B in 2024 to USD 3.18B by 2030. If accessible diagnosis is your mission too, let's talk.
Simplified view
One sample. One test, adjusted to routine lab workflows.
A respiratory sample is processed with standard lab methods, incubated with our reagents, then fixed for safe fluorescence reading — even up to 10 days later.
01.
Decontamination
Competing flora is cleared.
02.
Infect and express
Sample meets phage reagents.
03.
Fixation
Fixed — safe to handle and store.